Form PTO-892 U.S. Department of Commerce	Serial Number 10/022,276	Group Art Unit 1623	Attachment to Paper Number	12
Notice of References Cited	APPLICANT(S) **Gosselin et al.**			

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	5 9 3 9 4 0 2	08/17/99	**Weis et al. (I)**	514	044.000	03/11/98
*	B	5 5 5 9 1 0 1	09/24/96	**Weis et al. (II)**	514	045.000	10/24/94
*	C	6 0 2 5 3 3 5	02/15/00	**Weis et al. (III)**	514	044.000	09/21/95
	D	**6,395,716 B1**	05/28/02	**Gosselin et al.**	514	045.000	
	E	**5,990,093 A**	11/23/99	**Schinazi et al. (I)**	514	047.000	
	F	**6,245,749 B1**	06/12/01	**Schinazi et al. (II)**	514	047.000	

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	L	9 4 2 0 5 2 3	09/15/94	World(WO/PCT)	Burroughs Wellcome	------	------		
*	M	**EP 0 352 248 A1**	01/24/90	Europe(EPO)	**Medivir Ak.**	------	------		

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*		
*	R	**Robins**, "Selective Deoxygenation and Modification at C2' of Nucleosides," pages 1-4 in Nucleic Acids Research Symposium Series, Vol. No. 11, Kyoto, Japan, November 24-26, 1982, A. E. Pritchard (ed.), IRL Press, Ltd., Oxford, England, 1982; see also *Chemical Abstracts, 98*, Abstract No. 107670u (1982).
*	S	**Verri et al.**, "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," *Biochemical Journal, 328*(1), 317-320 (November 15, 1997).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER	DATE	page 1 of 2
L. E. Crane	09/16/02	¥: Reference not presently available.

*A copy of this reference is not being furnished with this office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number	12
Notice of References Cited	**10/022,276**	**1623**		
	APPLICANT(S) **Gosselin et al.**			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	T	**Lin et al.**, "Design and Synthesis of 2', 3'-Dideoxy-2', 3'-didehydro-ß-L-cytidine (ß-L-d4C) and 2', 3'-Dideoxy-2', 3'-didehydro-ß-L-5-fluorocytidine (ß-L-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) *In Vitro*, " *Journal of Medicinal Chemistry*, *39*(9), 1757-1759 (April 26, 1996).
*	U	**von Janta-Lipinski et al.**, "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified ß-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase But Not the Five Cellular DNA Polymerases α, ß, γ, δ, and ε Nor HIV-1 Reverse Transcriptase," *Journal of Medicinal Chemistry*, *41*(12), 2040-2046 (June 4, 1996).
*	V†	**Mansour et al.**, "Stereochemical Aspects of the Anti-HCMV Activity of Cytidine Nucleoside Analogues," *Antiviral Chemistry & Chemotherapy*, *6*(3), 138-142 (1995).
*	X†	**Spadari et al.**, "L-Thymidine Is Phosphorylated by Herpes Simplex Type 1 Thymidine Kinase and Inhibits Viral Growth," *Journal of Medicinal Chemistry*, *35*(22), 4214-4220 (1992).
*	Y	**Bryant et al.**, "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," *Antimicrobial Agents and Chemotherapy*, *45*(1), 229-235 (January, 2001).
*	Z†	**Wang et al.**, "Recovery of Liver Sinusoidal Endothelial Cell Function over Time After Hypothermic Preservation in Rat Orthotopic Liver Transplantation," AASLD Abstracts published in *Hepatology*, *24*(No. 4, Pt. 2), page 431A, Abstract No. 1219 (1996).††

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy supplied but not cited by applicant.

EXAMINER	DATE	page 2 of 2
L. E. Crane	09/16/02	¥: Reference not presently available.

*A copy of this reference is not being furnished with this office action.
(See Manual of Patent Examining Procedure, Section 707.05(a).)